Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Pearce IP celebrates milestone with IAM Patent Ranking

By Pearce IP | Jul 01, 2021

Read more

Pearce IP is proud to announce that our team has once again been ranked among the best patent practitioners in Australia by IAM Patent 1000. Both our litigation and prosecution team...
Sisters are doin' it for themselves: female inventors more likely to invent for women

By Naomi Pearce | Jun 30, 2021

Read more

A new report demonstrates that female-dominated inventor teams in biomedical sciences are more likely to invent female-focused inventions, but a lack of majority female inventor tea...
Words matter - Specification guides claim construction

By Naomi Pearce | Jun 30, 2021

Read more

Date: 30 June 2021Court: Full Court of the Federal Court of AustraliaJudges: Yates, Moshinsky and Burley JJ
Background
The case concerns Australian Patents 2003200627 (6...
Pearce IP announced as finalist for Lawyers Weekly Australian Law Awards 2021 “Intellectual Property Team of the Year”

By Pearce IP | Jun 29, 2021

Read more

Pearce IP is proud to announce that our team of patent and trademark lawyers and attorneys has been selected as a finalist for the Intellectual Property Team of the Year 2021 in the...
STADA and XBrane provide update on Xlucane™ (proposed ranibizumab biosimilar)

By Bioblast Editor | Jun 29, 2021

Read more

STADA and XBrane BioPharma announced that Xlucane™ (proposed ranibizumab biosimilar) met its primary endpoint in a pivotal comparability trial. STADA disclosed that it plans to submit the MAA and BLA for Xlucane™ to the EMA and FDA respectively in the second half of 2021.
New data on Luye Pharmaceuticals' proposed bevacizumab biosimilar published

By Bioblast Editor | Jun 29, 2021

Read more

A new study published in Cancer Communications concluded that Luye Pharmaceuticals’ LY01008 (proposed bevacizumab biosimilar) demonstrated similarity to reference Avastin® in terms of efficacy and safety in patients with advanced or recurrent non-squamous non-small cell lun...
Bioeq submits MAA for proposed ranibizumab biosimilar

By Bioblast Editor | Jun 29, 2021

Read more

Bioeq announced that it has submitted the MAA for FYB201 (proposed ranibizumab biosimilar) to the EMA. Under the agreement announced on 28 June 2021, FYB201 will be marketed in the EU by Teva.
Pearce IP BioBlast®: w/e 25 June 2021

By Naomi Pearce | Jun 28, 2021

Read more

23 Jun 21 | US | Genentech announced that the FDA has accepted the BLA for its Port Delivery System with ranibizumab under Priority Review. Genentech is seeking approval for its PDS...
Teva and Bioeq enter biosimilar ranibizumab agreement

By Bioblast Editor | Jun 28, 2021

Read more

Teva and Bioeq announced they have entered into a strategic partnership for the exclusive commercialisation of Bioeq’s FYB201 (proposed ranibizumab biosimilar). Under the agreement, Bioeq will be responsible for the development, registration and supply of the product, while...
NMPA approves sNDA for Tyvyt® (sintilimab) in combination with Byvasda® (biosimilar bevacizumab)

By Bioblast Editor | Jun 27, 2021

Read more

Innovent Biologics announced China’s National Medical Products Administration has approved its supplemental New Drug Application for Tyvyt® (sintilimab) in combination with Byvasda® (biosimilar bevacizumab) as a first-line treatment for people with advanced or unresectable ...